In addition, trastuzumab, a monoclonal antibody drug used for the therapy of HER2-overexpressing breast cancer, has been found to trigger macrophage-mediated phagocytic killing of cancer cells in vitro and in vivo [96]. This evidence concerns the gene ERBB2 and breast cancer.